Clinical trials: Anal Carcinoma
Prostate Carcinoma, Rectum Carcinoma
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation
Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when…
- Conditions
- Prostate Carcinoma, Rectum Carcinoma, Anal Canal Carcinoma, Endometrium Carcinoma
- Trial name
- MIFADORESOL (NCT04626466)
- Testing
- Biological investigations
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Anal Cancer
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00955240
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 20 sites in France
- Volunteers
- 16 people
- Sponsor
- UNICANCER
Squamous Cell Carcinoma of the Anus
Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer
The purpose of this study is assess the technical and operational feasibility of a specialised biopsy technique, sentinel lymph node biopsy (SLNB), in patients with anal cancer.
- Trial name
- R-SeNSAR (NCT02162641)
- Testing
- Sentinel lymph node biopsy
- Sponsor
- The Christie NHS Foundation Trust
Anal Cancer, Rectal Cancer
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma…
- Trial name
- NCT02399813
- Testing
- Axalimogene filolisbac
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Advaxis, Inc.
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Anal Cancer Patients, Perianal Patients
MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer
The purpose of this study is to establish a prospective database of anal canal and perianal cancer patients treated with IMRT and chemotherapy with curative intent at PMH for the purposes of investigating MRI-derived primary…
- Trial name
- NCT01053923
- Testing
- Magnetic Resonance Imaging (MRI)
- Sponsor
- University Health Network, Toronto
HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited…
- Conditions
- HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT06505551
- Testing
- SCG142, Cyclophosphamide, Fludarabine
- Volunteers
- 66 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Anal AIN3, Anal Carcinoma
Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients
Evaluation of the 3-years anal carcinoma (AC) incidence in patient with anal AIN3 lesions, and factors associated with this AC. A retrospective cohort study will be conducted (2000-2013) followed by a prospective cohort study…
- Trial name
- AIN3 (NCT01877135)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- French Society of Coloproctology
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are trans-activators of telomerase.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
- Trial name
- VolATIL (NCT03946358)
- Testing
- Blood sample collection, Tumor biopsies, CT scan
- Where
- 4 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Rectal Cancer, Colon Cancer
Molecular Genetic and Pathological Studies of Anal Tumors
Study the Genetics of Anal Cancer
- Conditions
- Rectal Cancer, Colon Cancer, Colonic Neoplasms, Anal Cancer
- Trial name
- NCT00267787
- Testing
- genetic analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Anal Squamous Cell Carcinoma, HIV Infections
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA.
- Trial name
- ACTION HIV (NCT05328765)
- Where
- 11 sites in Argentina, Brazil and 3 more
- Volunteers
- 369 people
- Sponsor
- Latin American Cooperative Oncology Group
Anus Cancer, Fecal Incontinence
Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)
High-grade squamous intraepithelial lesions (HSIL) and anal cancer are rising in incidence and at highest risk are HIV positive men who have sex with men (MSM).
- Conditions
- Anus Cancer, Fecal Incontinence, Anal Intraepithelial Neoplasia, Post Operative Pain
- Trial name
- FLAN (NCT04109573)
- Testing
- high resolution anal manometry
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Homerton University Hospital NHS Foundation Trust
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of Anal Canal
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity…
- Trial name
- NCT01382745
- Testing
- Nimotuzumab, Intensity Modulated Radiation Therapy (IMRT)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Dr. Te Vuong
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT07602842
- Testing
- IDP-001
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- InduPro, Inc.
Melanoma, Non-small Cell Lung Cancer
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04596033
- Testing
- GEN-011, IL-2, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genocea Biosciences, Inc.
Anal Cancer
Host Genome Methylation: a Screening Tool in Anal Cancer Detection
In January 2023, the first recommendations for anal cancer screening were issued by the French National Society of Coloproctology (SNFCP).
- Trial name
- AMethysT (NCT06792604)
- Testing
- Anal self-sampling (smear), HPV questionnaire
- Where
- 9 sites in France
- Volunteers
- 770 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anal Cancer
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
- Trial name
- REDEL (NCT05902533)
- Testing
- Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Cincinnati
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center